Corcept Therapeutics Incorporated reported significant financial performance in its latest 10-Q filing for the quarter ending June 30, 2026. The company achieved product revenue of $256.1 million for the three months ended June 30, 2026, a 31.7% increase from $194.4 million in the same period of 2025. For the first half of 2026, total product revenue reached $421.1 million, up from $351.6 million year-over-year. The growth was primarily driven by increased sales of its Hypercortisolism Products, which generated $208.6 million in the second quarter, and the recent launch of Lifyorli, which contributed $47.6 million in revenue since its introduction in April 2026.
In terms of profitability, Corcept reported a net income of $42.9 million for the second quarter of 2026, compared to $35.1 million in the same quarter of 2025. However, net income for the first half of 2026 was $11.2 million, a decrease from $55.7 million in the prior year, largely due to increased operating expenses. Total operating expenses rose to $214.8 million in the second quarter, up from $167.8 million in the same period last year, reflecting higher selling, general, and administrative costs associated with the commercialization of Lifyorli and other products.
Operationally, Corcept has made strategic advancements, including the FDA approval of Lifyorli in March 2026 for use in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer. The company has also expanded its product offerings with an authorized generic version of Korlym launched in June 2024. As of June 30, 2026, Corcept reported total assets of $888.7 million, an increase from $836.7 million at the end of 2025, with cash and cash equivalents totaling $111.0 million.
The company’s workforce has also seen changes, with increased employee headcount to support its expanding operations. Corcept's strategic focus on enhancing its product portfolio and market presence is evident, as it continues to invest in research and development, with R&D expenses totaling $53.9 million for the second quarter of 2026, down from $60.5 million in the same quarter of 2025. The company anticipates higher R&D spending in 2026 as it advances its clinical programs.
Looking ahead, Corcept remains optimistic about its growth trajectory, particularly with the anticipated FDA review of its resubmitted New Drug Application for relacorilant, which has a target date of December 17, 2026. The company expects to continue funding its operations and planned research activities without the need for additional capital, although it may consider raising funds for strategic purposes. Overall, Corcept's financial and operational developments position it well for future growth in the biopharmaceutical market.
About CORCEPT THERAPEUTICS INC
Corcept Therapeutics develops medications that modulate cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its core products include Korlym and relacorilant for hypercortisolism, with ongoing trials for cancer, liver disease, ALS, and metabolic conditions. The company leverages proprietary cortisol modulators, patents, and strategic collaborations to address unmet medical needs in hormone regulation and cancer therapy.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov